The FDA gave its approval to proceed with an early-stage trial of Ziopharm Oncology's chimeric antigen receptor T-cell therapy as a treatment for relapsed CD19+ leukemias and lymphomas. The study will include up to 24 patients who have experienced relapses following allogeneic bone marrow transplantation, and the cells will be produced using a rapid personalized manufacture technique.
FDA clears trial of personalized CD19-specific CAR T-cell therapy
Sign up for AIChE SmartBrief
News for chemical engineers
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.